Home › Funds › Atle Fund Management AB › TNGX
Atle Fund Management AB position in TNGX
Tango Therapeutics, Inc. · Health Care
Atle Fund Management AB reported holding 184,394 shares of TNGX (Tango Therapeutics, Inc.) in its Q3 2026 13F filing — a position valued at US$4.6M, representing 1.23% of its reported portfolio and ranking #28 among its reported holdings. Atle Fund Management AB has disclosed TNGX holdings in 3 of the last 3 reported quarters, going back to Q1 2026.
Last updated: 2026-11-12 · Source: SEC EDGAR Form 13F-HR
How Atle Fund Management AB's TNGX position evolved
Atle Fund Management AB first disclosed a stake in TNGX in Q1 2026 at 29,915 shares (US$3.6M). The position peaked in Q2 2026 at 198,557 shares, worth US$6.2M. Across 3 filings, Atle Fund Management AB increased the stake 1 time(s), trimmed it 1 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 184,394 shares valued at US$4.6M — a reduction of -14,163 shares quarter over quarter.. Notable position changes include a 564% increase in Q2 2026 (shares fell 20% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2026 | 29.91K | $3.63M | New |
| Q2 2026 | 198.56K | $6.21M | Add |
| Q3 2026 | 184.39K | $4.60M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About TNGX and 13F data
TNGX (Tango Therapeutics, Inc.) is a Health Care company. 85 other funds we track also report a position in TNGX — the largest reported positions include RTW INVESTMENTS, LP (US$434.5M), Farallon Capital Management (US$383.8M), FARALLON CAPITAL MANAGEMENT, L.L.C. (US$383.8M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding TNGX
- RTW INVESTMENTS, LP 13.90M sh · $434.53M · Q2 2026
- Farallon Capital Management 12.28M sh · $383.78M · Q2 2026
- FARALLON CAPITAL MANAGEMENT, L.L.C. 12.28M sh · $383.78M · Q2 2026
- Boxer Capital Management, LLC 10.88M sh · $339.99M · Q2 2026
- TCG Crossover Management, LLC 9.08M sh · $283.88M · Q2 2026
- Paradigm Biocapital Advisors LP 6.36M sh · $198.74M · Q2 2026
- Siren, L.L.C. 6.78M sh · $169.26M · Q3 2026
- Deep Track Capital, LP 4.20M sh · $131.29M · Q2 2026
- DEERFIELD MANAGEMENT COMPANY, L.P. 4.19M sh · $131.00M · Q2 2026
- Woodline Partners LP 4.00M sh · $125.06M · Q2 2026
- TRV GP IV, LLC 6.37M sh · $120.18M · Q2 2026
- PERCEPTIVE ADVISORS LLC 3.38M sh · $105.57M · Q2 2026
More on Atle Fund Management AB
FAQ
How long has Atle Fund Management AB held TNGX?
Atle Fund Management AB has disclosed TNGX holdings in 3 of the last 3 reported quarters, going back to Q1 2026.
What is Atle Fund Management AB's current position in TNGX?
As of Q3 2026, Atle Fund Management AB holds 184.39K shares of TNGX (Tango Therapeutics, Inc.), valued at $4.60M, representing 1.23% of its reported portfolio and ranking #28.
Has Atle Fund Management AB been buying or selling TNGX?
In the latest 13F filing (Q3 2026), Atle Fund Management AB reduced its position in TNGX. The position peaked in Q2 2026 at 198.56K shares.
Which other funds hold TNGX?
Other major institutional holders of TNGX include RTW INVESTMENTS, LP, Farallon Capital Management, FARALLON CAPITAL MANAGEMENT, L.L.C., among 85 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.